← Back to Search

Communication Strategies for End-of-Life Cancer Care ((PATH-SIC) Trial)

N/A

Waitlist Available

Led By Christopher Manz, MD

Research Sponsored by Dana-Farber Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up randomization up to 1 year

Awards & highlights

(PATH-SIC) Trial Summary

This trial aims to improve end-of-life care for cancer patients by talking about their hopes & wishes with their oncologist.

Who is the study for?

This trial is for adults with certain types of cancer (urogenital, breast, gastrointestinal, gynecologic, genitourinary, or lung) who have a poor prognosis and an upcoming appointment at specific Dana Farber Cancer Institute oncology clinics. Those already having serious illness conversations documented or previously enrolled in this trial are excluded.Check my eligibility

What is being tested?

The PATH-SIC study tests whether sending nudge emails to clinicians and letters plus questionnaires to patients can increase meaningful discussions about healthcare goals and end-of-life care preferences between cancer patients and their doctors.See study design

What are the potential side effects?

Since the interventions involve communication strategies rather than medical treatments, traditional physical side effects are not expected. However, participants may experience emotional or psychological impacts from engaging in serious illness conversations.

(PATH-SIC) Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ randomization up to 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~randomization up to 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and randomization up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of patients with an SIC at 60 days for arm 1 (patient +clinician nudge) vs arm 2 (no nudge).

Secondary outcome measures

Death in an acute care facility

Death in the ICU

ED visits in the last 30 days of life

+9 more

(PATH-SIC) Trial Design

4Treatment groups

Experimental Treatment

Active Control

Group I: Patient receives a nudge but not the clinicianExperimental Treatment1 Intervention

-Patient nudge consists of a letter and SHARE questionnaire

Group II: Clinician receives a nudge but not the patientExperimental Treatment1 Intervention

-Clinician "nudge" email encouraging discussion to initiate discussion on SIC

Group III: Both patient and clinician receive a nudgeExperimental Treatment2 Interventions

Patient nudge consists of a letter and SHARE questionnaire Clinician "nudge" email encouraging discussion to initiate discussion on SIC

Group IV: Neither the patient nor clinician receive a nudgeActive Control1 Intervention

Standard Care

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor

1,079 Previous Clinical Trials

340,148 Total Patients Enrolled

141 Trials studying Breast Cancer

21,817 Patients Enrolled for Breast Cancer

Christopher Manz, MDPrincipal InvestigatorDana-Farber Cancer Institute

Media Library

Breast Cancer Research Study Groups: Neither the patient nor clinician receive a nudge, Both patient and clinician receive a nudge, Patient receives a nudge but not the clinician, Clinician receives a nudge but not the patient

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any remaining slots in this investigation open to new participants?

"Currently, this medical study is not enrolling participants. It was initially posted on 28th November 2022 and most recently edited the following month. Nonetheless, there are 1625 other clinical trials recruiting patients at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)

Christopher Manz, MD 2022. "Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05629065.